IMTX241220C9000
- 0.68
- 0.000.00%
Immatics Newsroom
Immatics N.V. Reports Strong Q3 2024 Progress and Financials
Goldman Sachs Initiates Immatics(IMTX.US) With Buy Rating, Announces Target Price $13.5
Immatics Moved to Buy From Not Rated at Goldman Sachs
Earnings Update: Immatics N.V. (NASDAQ:IMTX) Just Reported And Analysts Are Boosting Their Estimates
Immatics Analyst Ratings
BofA Securities Maintains Immatics(IMTX.US) With Buy Rating, Maintains Target Price $15
Jefferies Maintains Immatics(IMTX.US) With Buy Rating, Maintains Target Price $20
BofA Securities Maintains Immatics(IMTX.US) With Buy Rating, Cuts Target Price to $15
Leerink Partners Maintains Immatics(IMTX.US) With Buy Rating, Announces Target Price $18
Immatics Price Target Lowered to $18 From $19 at Leerink
What Makes Immatics (IMTX) a New Buy Stock
Express News | Immatics NV : Piper Sandler Cuts Target Price to $18 From $19
Immatics Sees Revenue Surge Despite R&D Expenses
Immatics Sees Cash Runway Into 2H27
Immatics N.V. Reports Promising Clinical Data for TCR Bispecific Molecules and Advances Four Cancer Therapy Candidates
Immatics GAAP EPS of -€0.11, Revenue of €50.56M
Immatics: Q3 Earnings Snapshot
Immatics 3Q Loss/Shr EUR0.11 >IMTX
Immatics 3Q Loss EUR8.57M >IMTX
Press Release: Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER(R) IMA402 Targeting PRAME